Market Overview

UPDATE: Ariad Pharmaceuticals Downgraded by Citigroup

Related ARIA
Morning Market Movers
Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals
Wayfair Rises, Westport Innovations Cuts Forecast (Fox Business)

In a report published on Monday, lead analyst Yaron Werber downgraded Ariad Pharmaceuticals (NYSE: ARIA) from a Neutral/High Risk to Sell/High Risk yet raising price target to $5.50 from $2.50.

The reported stated, “While the earlier than expected return of Iclusig to the US market is a positive, we expect the re-launch to be challenging with a tightly restricted label and headwinds from the current safety profile. We see more potential for negative surprise over the next 12-mos +model lower sales ests than consensus.”

ARIA closed Friday at $7.15 and is currently trading at $6.71.

Latest Ratings for ARIA

DateFirmActionFromTo
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform
Jun 2014UBSMaintainsNeutral

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Downgrades Price Target Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Get Benzinga's Newsletters